Clinical trial · Observational
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
NCT05403177CI-TRIAL-00114320MOHCCN-OrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Ovary Cancer | — | UNRESOLVED | — |
| Pancreas Cancer | Pancreatic Carcinoma |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- MOHCCN-O
- description
- Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.
Primary outcomes (1)
- measure
- Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data
- timeFrame
- 5 years
- description
- Consolidate and annotate data from patients included in a pan-Canadian cohort
Secondary outcomes (3)
- measure
- Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: 1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1) 2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization 3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling. 4. Participating patients must agree to share their anonymized clinical and genomic data Exclusion Criteria: None.
References
Publications (0)
Data not yet available
No reference posted for this study.